Abstract
This commentary outlines the strategy employed by a multidisciplinary immune‐related toxicity team to evaluate patients who may be at high risk for the development of immune‐related toxicity, in particular, those with preexisting lung conditions and subsequent immune‐related pneumonitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have